Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)

• Main Authors: Andrea Sturchio, Luca Marsili, Joaquin A. Vizcarra, Alok K. Dwivedi, Marcelo A. Kauffman, Andrew P. Duker, Peixin Lu, Michael W. Pauciulo, Benjamin D. Wissel, Emily J. Hill, Benjamin Stecher, Elizabeth G. Keeling, Achala S. Vagal, Lily Wang, David B. Haslam, Matthew J. Robson, Caroline M. Tanner, Daniel W. Hagey, Samir El Andaloussi, Kariem Ezzat, Ronan M. T. Fleming, Long J. Lu, Max A. Little, Alberto J. Espay
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2020-10-01
• Series: Frontiers in Aging Neuroscience
• Subjects: biomarkers; Parkinson’s disease; Alzheimer’s disease; neurodegeneration; cohort; drug repurposing
• Online Access: https://www.frontiersin.org/article/10.3389/fnagi.2020.553635/full

Ongoing biomarker development programs have been designed to identify serologic or imaging signatures of clinico-pathologic entities, assuming distinct biological boundaries between them. Identified putative biomarkers have exhibited large variability and inconsistency between cohorts, and remain inadequate for selecting suitable recipients for potential disease-modifying interventions. We launched the Cincinnati Cohort Biomarker Program (CCBP) as a population-based, phenotype-agnostic longitudinal study. While patients affected by a wide range of neurodegenerative disorders will be deeply phenotyped using clinical, imaging, and mobile health technologies, analyses will not be anchored on phenotypic clusters but on bioassays of to-be-repurposed medications as well as on genomics, transcriptomics, proteomics, metabolomics, epigenomics, microbiomics, and pharmacogenomics analyses blinded to phenotypic data. Unique features of this cohort study include (1) a reverse biology-to-phenotype direction of biomarker development in which clinical, imaging, and mobile health technologies are subordinate to biological signals of interest; (2) hypothesis free, causally- and data driven-based analyses; (3) inclusive recruitment of patients with neurodegenerative disorders beyond clinical criteria-meeting patients with Parkinson’s and Alzheimer’s diseases, and (4) a large number of longitudinally followed participants. The parallel development of serum bioassays will be aimed at linking biologically suitable subjects to already available drugs with repurposing potential in future proof-of-concept adaptive clinical trials. Although many challenges are anticipated, including the unclear pathogenic relevance of identifiable biological signals and the possibility that some signals of importance may not yet be measurable with current technologies, this cohort study abandons the anchoring role of clinico-pathologic criteria in favor of biomarker-driven disease subtyping to facilitate future biosubtype-specific disease-modifying therapeutic efforts.